Paper36712976
Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma.
Akl MG and 1 other. Front Cell Dev Biol, 2022. Cited by 3 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Immunometabolic factors contributing to obesity-linked hepatocellular carcinoma. Papers, record 36712976. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36712976
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References248
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23,223,452 | JNK expression by macrophages promotes obesity-induced insulin resistance and inflammation. | Science | 2013 | https://conductscience.org/library/papers/23223452 | PubMed |
| 2 | 24,363,061 | Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma. | Tumour Biol | 2014 | https://conductscience.org/library/papers/24363061 | PubMed |
| 3 | 26,301,053 | Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. | World J Hepatol | 2015 | https://conductscience.org/library/papers/26301053 | PubMed |
| 5 | 2,822,019 | Role of fructose 2,6-bisphosphate in the control of glycolysis in mammalian tissues. | Biochem J | 1987 | https://conductscience.org/library/papers/2822019 | PubMed |
| 6 | 25,125,077 | Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. | Hepatology | 2015 | https://conductscience.org/library/papers/25125077 | PubMed |
| 7 | 34,570,916 | Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non-alcoholic fatty liver disease assessed by magnetic resonance imaging. | Aliment Pharmacol Ther | 2021 | https://conductscience.org/library/papers/34570916 | PubMed |
| 8 | 29,449,774 | Reactive Oxygen Species: A Key Constituent in Cancer Survival. | Biomark Insights | 2018 | https://conductscience.org/library/papers/29449774 | PubMed |
| 9 | 26,807,645 | Hypoxia and metabolic adaptation of cancer cells. | Oncogenesis | 2016 | https://conductscience.org/library/papers/26807645 | PubMed |
| 10 | 18,650,514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 11 | 29,159,325 | Role of Aramchol in steatohepatitis and fibrosis in mice. | Hepatol Commun | 2017 | https://conductscience.org/library/papers/29159325 | PubMed |
| 12 | 34,027,340 | Genetic predisposition similarities between NASH and ASH: Identification of new therapeutic targets. | JHEP Rep | 2021 | https://conductscience.org/library/papers/34027340 | PubMed |
| 13 | 30,665,869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 14 | 29,274,776 | Nrf2-p62 autophagy pathway and its response to oxidative stress in hepatocellular carcinoma. | Transl Res | 2018 | https://conductscience.org/library/papers/29274776 | PubMed |
| 15 | 26,138,654 | Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis. | Dig Dis Sci | 2015 | https://conductscience.org/library/papers/26138654 | PubMed |
| 16 | 24,978,903 | TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. | Nat Commun | 2014 | https://conductscience.org/library/papers/24978903 | PubMed |
| 17 | 32,231,263 | Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. | Nat Rev Mol Cell Biol | 2020 | https://conductscience.org/library/papers/32231263 | PubMed |
| 18 | 34,439,245 | Dietary and Genetic Cholesterol Loading Rather Than Steatosis Promotes Liver Tumorigenesis and NASH-Driven HCC. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34439245 | PubMed |
| 19 | 32,483,353 | Single-cell technologies in hepatology: new insights into liver biology and disease pathogenesis. | Nat Rev Gastroenterol Hepatol | 2020 | https://conductscience.org/library/papers/32483353 | PubMed |
| 20 | 33,824,298 | Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation. | Cell Death Dis | 2021 | https://conductscience.org/library/papers/33824298 | PubMed |
| 21 | 29,717,933 | The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. | Physiol Rev | 2018 | https://conductscience.org/library/papers/29717933 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,316,223 | Combined C-terminal truncation and point mutations in HBx in genotype D1 HBV-associated hepatocellular carcinoma. | Infect Agent Cancer | 2026 | https://conductscience.org/library/papers/42316223 | PubMed |
| 41,664,365 | Lapatinib Promotes Apoptosis in Hepatoma Cells by Regulating SPP1 Expression. | Anticancer Agents Med Chem | 2026 | https://conductscience.org/library/papers/41664365 | PubMed |
| 39,125,617 | Protective Effects of Hepatocyte Stress Defenders, Nrf1 and Nrf2, against MASLD Progression. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39125617 | PubMed |
Genes51
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36712976
GET https://conductscience.org/api/papers/v1/36712976/references?page=2